Medications

Bevacizumab may cause cognitive impairment

Glioblastoma is the most common kind of brain tumour in adults. It is a very aggressive form of cancer; patients with this diagnosis have a median post-diagnosis survival of 15 months. Especially in the US, the drug Bevacizumab ...

Cancer

Why some brain tumors respond to immunotherapy

Columbia researchers have learned why some glioblastomas—the most common type of brain cancer—respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy ...

Cancer

New tool gives deeper understanding of glioblastoma

Researchers in the lab of Charles Danko at the Baker Institute for Animal Health have developed a new tool to study genetic "switches" active in glioblastoma tumors that drive growth of the cancer. In a new paper in Nature ...

Cancer

Brain cancer survival has improved – but not much for elderly

A new study from Helsinki University Hospital, University of Helsinki and the Finnish Cancer Registry shows that survival after glioblastoma has improved since the millennium. The improvement in survival was, however, modest ...

Cancer

TTFields tied to improved survival in glioblastoma patients

(HealthDay)—For patients with glioblastoma, the addition of tumor-treating fields (TTFields) to standard treatment with temozolomide is associated with improved survival without negative effects on health-related quality ...

Cancer

Vulnerability identified for subtypes of glioblastoma

Glioblastoma, the most common and aggressive form of brain cancer, typically fails to respond to treatment or rapidly becomes drug resistant. In a paper published online in the journal Cancer Cell on November 30, University ...

page 1 from 2